Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

NCT01348100 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Iloperidone crystalline formulation
DRUG: Iloperidone microparticle formulation
DRUG: Oral iloperidone

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]